Medivation, Inc. (MDVN) said Monday that it has submitted a New Drug Application to the U.S. Food and Drug Administration for enzalutamide, formerly MDV3100.
The compound has been studied in patients with castration-resistant prostate cancer who have received docetaxel therapy.
The FDA is expected to determine within 60 days whether to accept the filing for review.
Medivation said it has requested Priority Review, a designation given to drugs that offer a significant improvement in treatment or provide treatment where no satisfactory alternative therapy exists.
If a Priority Review is granted, the FDA goal for completing a review is six months.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.